A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leuk...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P., Kantarjian, H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3886799/
https://ncbi.nlm.nih.gov/pubmed/24180494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1306494
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk